Join
Live feed
·
PRReleasevia Quantisnow
Lyell Immunopharma Inc. logo

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

ByQuantisnow·Wall Street's wire, on your screen.
LYEL· Lyell Immunopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LYEL (Lyell Immunopharma Inc.) and more on Quantisnow.